FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid... (ency (EMEA) for Cimzia(R) in thetreatmen...)

FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis

Date:2/6/2008

ency (EMEA) for Cimzia(R) in the treatment of RA is ongoing, with filing planned in the first half of 2008.

In September 2007, Cimzia(R) was approved in Switzerland for the treatment of Crohn's disease and it was launched in January 2008.

About Rheumatoid Arthritis

RA is a progressive autoimmune disease that causes chronic inflammation of the joints. It is estimated that five million people suffer from RA globally, with 0.3 percent to 1 percent of the population in industrialized countries suffering from the disease. Women are three times more likely to be affected than men. Although it can affect people of all ages, the onset of RA usually occurs between the ages of 35-55.

Traditional treatments for RA include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs), with biological therapies a more recent addition.

About UCB

UCB, Brussels, Belgium (http://www.ucb-group.com) is a global leader in the biopharmaceutical industry dedicated to the research, development and commercialization of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology. UCB focuses on securing a leading position in severe disease categories. Employing around 12,000 people in over 40 countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro forma basis. UCB S.A. is listed on Euronext Brussels.

UCB Forward-Looking Statement

This news release contains forward-looking statements that involve risks and uncertainties, including statements with respect to the development and commercialization of certolizumab pegol. Among the factors that could cause actual results to differ materially from those indicated by such forward- looking statements are: the results of research, development and clinical trial
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
2. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
5. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
11. AEterna Zentaris Announces Outcome of Managements Strategic Review

Post Your Comments:

FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid...(ency (EMEA) for Cimzia(R) in thetreatmen...)